FILTER
LATEST INTERVIEWS
Jody Kuzenko
PRESIDENT AND CEO, TOREX GOLD RESOURCES
"With US$508 million left to spend on the Media Luna project south of the river, we have a strong, cash-producing asset at ELG that is financing the construction of our future."
Marc Sale
CEO, FIRST CLASS METALS
"With four permitted drill targets, each equivalent to a primary project for many exploration companies, we are poised for an exciting future."
Miguel Benedetto
MANAGING DIRECTOR, NATIONAL CHEMICAL INDUSTRY ASSOCIATION (ANIQ)
"From the perspective of the chemical industry, the macroeconomic position of the country is very strong. We continue to grow the levels of investment."
Marco Salcedo
DIRECTOR, AMVAC
"2023 has been a tough year for several industries, including the agrochemical industry in Mexico."
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
"There are signs of funding returning in the first half of this year, potentially revitalizing early-stage projects, and benefiting the CDMO sector."
Shane Williams
PRESIDENT AND CEO, WEST RED LAKE GOLD MINES
"Our long-term vision is to emulate the success of mid-tier producers like Gold Corp and Kirkland Lake."
Julien Lawrence
MANAGING DIRECTOR, O2 MINING
"O2 Mining fits in the gaps between traditional consultants and contracted operators."
Colin Moorhead
EXECUTIVE CHAIRMAN AND MANAGING DIRECTOR, XANADU MINES
"Kharmagtai is strongly positioned to become Mongolia’s next large-scale copper mine amongst only a handful of new global mines delivering copper within the next 4 years."
Tom Di Francesco
GENERAL MANAGER, B&D MANUFACTURING
"In my experience, the mining world feels interconnected, and Sudbury serves as a focal point."
Simon Meadows Smith
MANAGING DIRECTOR, SEMS EXPLORATION
"We believe technology should enhance, not replace, the role of geologists in exploration."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
